Product Description
Mechanisms of Action: SNR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Belgium | Czech | India | Ireland | Korea | Luxembourg | Malta | Netherlands | New Zealand | Pakistan | Portugal | Saudi Arabia | Singapore | Slovakia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Infrastructure and the Environment
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Depressive Disorder
Phase 3: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03126188 |
T/IM-F/Psych/15/20 | N/A |
Completed |
Depressive Disorder |
2017-12-31 |
2025-02-04 |
Primary Endpoints|Treatments |
|
2023-506617-21-00 |
INTENSIFY MDD | P3 |
Recruiting |
Depressive Disorder, Major |
2026-06-30 |
2025-05-02 |
Treatments |
|
2013-004936-31 |
2013-004936-31 | P4 |
Completed |
Depressive Disorder |
2016-05-28 |
2022-03-13 |
Treatments |